Exploitation of immune mechanisms in the treatment of central nervous system cancer.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Seminars in Pediatric Neurology

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/PB.2000.6691PMID 10914414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical effect of interferon in malignant brain tumours

  2005cited by this paper
• Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells

  2004cited by this paper
• Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor

  2004cited by this paper
• Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene.

  1999cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Mechanisms of interferon action.

  1998cited by this paper
• Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.

  1998cited by this paper
• Interleukin-12-based immunotherapy against rat 9L glioma.

  1998cited by this paper
• Systemic T cell adoptive immunotherapy of malignant gliomas.

  1998cited by this paper
• New Paths in Human Cancer Serology

  1998cited by this paper
• Bone marrow‐derived dendritic cells pulsed with a tumor‐specific peptide elicit effective anti‐tumor immunity against intracranial neoplasms

  1998cited by this paper
• Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes.

  1998cited by this paper
• Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

  1998cited by this paper
• A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.

  1997cited by this paper
• Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

  1997cited by this paper
• Analysis of B7-1 and B7-2 costimulatory ligands in cultured mouse microglia: upregulation by interferon-gamma and lipopolysaccharide and downregulation by interleukin-10, prostaglandin E2 and cyclic AMP-elevating agents.

  1997cited by this paper
• Immunobiology of Gliomas: New Perspectives for Therapy a

  1997cited by this paper
• The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium.

  1997cited by this paper
• Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.

  1997cited by this paper
• Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.

  1997cited by this paper
• Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity.

  1997cited by this paper
• Advances in the biological therapy and gene therapy of malignant disease.

  1997cited by this paper
• Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.

  1997cited by this paper
• The selective engulfment of apoptotic bodies by dendritic cells is mediated by the αvβ3 integrin and requires intracellular and extracellular calcium

  1997cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 Gene

  1997cited by this paper
• IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells.

  1997cited by this paper
• Gene transfer of suicide genes for the treatment of malignant gliomas: efficacy, limitations, and perspectives for a combined immunotherapy.

  1997cited by this paper
• Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors.

  1996cited by this paper
• Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.

  1996cited by this paper
• Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/IV astrocytoma

  1996cited by this paper
• Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.

  1996cited by this paper
• Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells.

  1995cited by this paper
• The Costimulatory Molecule B7 is Expressed on Human Microglia in Culture and in Multiple Sclerosis Acute Lesions

  1995cited by this paper
• RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma.

  1995cited by this paper
• Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy.

  1995cited by this paper
• Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.

  1995cited by this paper
• Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.

  1995cited by this paper
• Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.

  1995cited by this paper
• B7/BB‐1 antigen expression on adult human microglia studied in vitro and in situ

  1994cited by this paper
• Brain tumors in children.

  1994cited by this paper
• Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma.

  1994cited by this paper
• Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.

  1994cited by this paper
• In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.

  1994cited by this paper
• Tumor‐derived transforming growth factor‐β1 and interleukin‐6 are chemotactic for lymphokine‐activated killer cells

  1994cited by this paper
• Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

  1994cited by this paper
• The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

  1993cited by this paper
• Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro.

  1993cited by this paper
• Generation of cellular immune responses against a glioma-associated antigen(s).

  1993cited by this paper
• Transforming growth factor-beta 1 is chemotactic for interleukin-2-activated natural killer cells.

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

  1993cited by this paper
• Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element.

  1993cited by this paper
• The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

  1993cited by this paper
• Treatment of glioma by engineered interleukin 4-secreting cells.

  1993cited by this paper
• Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view.

  1992cited by this paper
• Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy

  1992cited by this paper
• Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.

  1992cited by this paper
• Polyethylene‐glycol‐modified interleukin‐2 is superior to interleukin‐2 in locoregional immunotherapy of established guinea‐pig tumors

  1992cited by this paper
• Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.

  1992cited by this paper
• Brain macrophages: evaluation of microglia and their functions.

  1992cited by this paper
• Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor

  1992cited by this paper
• Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes.

  1992cited by this paper
• Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I.

  1992cited by this paper
• Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia.

  1992cited by this paper
• Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes.

  1992cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.

  1991cited by this paper
• Modulation of human leukocyte antigenDR expression in glioblastoma cells by interferon gamma and other cytokines.

  1991cited by this paper
• Malignant glioma modulation of immune function: relative contribution of different soluble factors.

  1991cited by this paper
• Modulation of T-cell function by gliomas.

  1991cited by this paper
• Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.

  1991cited by this paper
• Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes.

  1990cited by this paper
• Immunobiology of brain tumors.

  1990cited by this paper
• Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

  1989cited by this paper
• Immunological reactions induced by intracerebral transplantation: evidence that host microglia but not astroglia are the antigen-presenting cells.

  1989cited by this paper
• Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

  1989cited by this paper
• Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2.

  1989cited by this paper
• Systemic beta-interferon therapy for recurrent gliomas: a brief report.

  1989cited by this paper
• In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.

  1988cited by this paper
• Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas.

  1988cited by this paper
• Transforming growth factor‐β2 down‐regulates HLA‐DR antigen expression on human malignant glioma cells.

  1988cited by this paper
• Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

  1988cited by this paper
• Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.

  1988cited by this paper
• Rat ependyma and microglia cells express class II MHC antigens after intravenous infusion of recombinant gamma interferon.

  1988cited by this paper
• Systemic gamma-interferon therapy for recurrent gliomas.

  1988cited by this paper
• Suppression of splenic natural killer cell activity in rats with brain tumors.

  1988cited by this paper
• Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.

  1988cited by this paper
• Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

  1987cited by this paper
• T cell suppressor factor from human glioblastoma cells is a 12.5‐kd protein closely related to transforming growth factor‐beta.

  1987cited by this paper
• Graft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system.

  1987cited by this paper
• Cellular immune reactivity within the CNS

  1986cited by this paper
• Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

  1986cited by this paper
• Functional capacity of solid tissue transplants in the brain: evidence for immunological privilege

  1985cited by this paper
• THE DETAILED DISTRIBUTION OF HLA‐A, B, C ANTIGENS IN NORMAL HUMAN ORGANS

  1984cited by this paper
• Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies.

  1984cited by this paper
• Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme

  1984cited by this paper
• Regulation of natural killer cell function by glass-adherent cells in patients with primary intracranial malignancies.

  1984cited by this paper
• THE DETAILED DISTRIBUTION OF MHC CLASS II ANTIGENS IN NORMAL HUMAN ORGANS

  1984cited by this paper
• Inducible expression of H–2 and Ia antigens on brain cells

  1984cited by this paper

• CURRENT TRENDS IN MEDICAL AND CLINICAL CASE REPORTS

  2020cites this paper
• El cáncer como inmunodeficiencia secundaria. Revisión

  2016cites this paper
• Common Denominators of Self-renewal and Malignancy in Neural Stem Cells and Glioma

  2012cites this paper
• Dendritic cell-based immunotherapy for malignant glioma

  2008cites this paper
• Dendritic cell-based immunotherapy for malignant glioma

  2008cites this paper
• 19 – Transplants for Glioblastoma

  2007cites this paper
• Tumors of the brain and spine

  2007cites this paper
• RECENT ADVANCES IN THE TREATMENT OF CHILDHOOD BRAIN TUMORS

  2005cites this paper
• Dendritic cell-based immunotherapy for malignant gliomas

  2005cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2005cites this paper
• Harnessing the Immune System Against Human Glioma

  2005cites this paper
• Autologous Adjuvant Linked Fibroblasta Induce Anti-Glioma Immunity: Implications for Development of a Glima Vaccine

  2004cites this paper
• Proton radiation and TNF-alpha/Bax gene therapy for orthotopic C6 brain tumor in Wistar rats.

  2004cites this paper
• Proton Radiation and TNF-α/Bax Gene Therapy for Orthotopic C6 Brain Tumor in Wistar Rats

  2004cites this paper
• Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

  2004cites this paper
• The role of transforming growth factor-beta in primary brain tumors.

  2003cites this paper
• Biology and therapy of malignant solid tumors in childhood.

  2003cites this paper
• Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine

  2003cites this paper
• Immunotherapeutic approach of experimental brain tumor with a corpuscular antigen

  2003cites this paper
• Justification of glioma biology beyond a cellular basis of interpretation.

  2003cites this paper
• CHAPTER 10 – Interleukin-4

  2003cites this paper
• Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas.

  2002cites this paper
• Biology and therapy of malignant solid tumors in childhood.

  2002cites this paper
• 7-Hydroxystaurosporine-induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells and Yields a Potent Vaccine Strategy in an Intracranial Glioma Model

  2002cites this paper
• Dendritic Cell Therapy of Primary Brain Tumors

  2001cites this paper
• Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors.

  2001cites this paper
• Gliomagenesis: genetic alterations and mouse models

  2001cites this paper
• Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.

  2001cites this paper
• Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

  2000cites this paper
• Essential for Protective Immunity T Cells by Interleukin-4-transfected 9 L Gliosarcoma Is + Cytokine Gene Therapy of Gliomas : Induction of Reactive CD 4 Updated Version

  2000cites this paper